HeartSciences Inc. (HSCS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

HeartSciences Inc. (HSCS) Healthcare & Pipeline Overview

HeartSciences Inc. is a medical technology company specializing in AI-enhanced electrocardiogram (AI-ECG) solutions for cardiac diagnostics. The firm develops the MyoVista wavECG device and MyoVista Insights platform, integrating artificial intelligence to detect impaired cardiac relaxation and other cardiac dysfunctions, thereby augmenting the clinical utility of conventional ECG data.

What Is the Investment Thesis for HSCS?

HeartSciences Inc. (HSCS) is positioned within the growing medical technology sector, focusing on AI-enhanced ECG solutions for cardiac diagnostics. The company's MyoVista wavECG device and MyoVista Insights platform represent key value drivers, aiming to improve early detection and comprehensive assessment of cardiac dysfunction. The integration of AI into traditional ECGs addresses a significant market need for more precise and actionable diagnostic information, potentially leading to earlier intervention and improved patient outcomes. Growth catalysts include successful regulatory approvals for its AI-ECG algorithms and devices, followed by robust commercialization efforts to drive adoption in clinical settings. The cloud-based MyoVista Insights platform offers scalability, allowing the company's AI algorithms to be deployed across various ECG hardware systems, expanding potential revenue streams beyond its proprietary device. However, the company's small market capitalization of $7.32M indicates potential vulnerability to market fluctuations and challenges in securing further funding, representing a key risk factor for investors to monitor. Operational efficiency is also a concern, with a reported profit margin of -97881.0% and a gross margin of -1060.2%, highlighting the significant investment required in R&D and commercialization phases.

Based on FMP financials and quantitative analysis

HSCS Key Highlights

Market Capitalization: HeartSciences Inc. currently holds a market capitalization of $7.32M, reflecting its early-stage development and smaller scale within the medical technology sector.

• Profit Margin: The company reported a profit margin of -97881.0%, indicating substantial losses as it invests heavily in research, development, and commercialization of its AI-ECG solutions.
• Gross Margin: HeartSciences Inc. has a gross margin of -1060.2%, suggesting that the cost of goods sold significantly exceeds revenue, typical for companies in pre-revenue or early commercialization phases with high R&D expenditures.
• Beta: With a Beta of 1.97, HSCS exhibits higher volatility compared to the overall market, implying its stock price movements are nearly twice as sensitive to market fluctuations.
• Employee Base: The company operates with a lean team of 15 employees, focusing its resources on specialized development and strategic initiatives in AI-enhanced cardiac diagnostics.

Who Are HSCS's Competitors?

HSCS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are HSCS's Key Strengths?

Proprietary AI-enhanced ECG technology, including the MyoVista wavECG device and MyoVista Insights platform.

• Addresses a significant clinical need for improved early detection of cardiac dysfunction.
• Cloud-based platform allows for scalable deployment of AI algorithms across various ECG hardware systems.
• Focus on augmenting the clinical utility of widely used ECGs, potentially accelerating adoption.

What Are HSCS's Weaknesses?

Small market capitalization ($7.32M) indicates potential vulnerability and limited financial resources.

• Significant negative profit (-97881.0%) and gross (-1060.2%) margins reflect high operational costs and early commercialization phase.
• Reliance on regulatory approvals for market entry and expansion.
• Small employee base (15 employees) may limit rapid scaling and broad market reach.

What Could Drive HSCS Stock Higher?

HSCS catalyst: Achievement of key regulatory approvals (e.g., FDA clearance) for new or enhanced AI-ECG algorithms and the MyoVista wavECG device, enabling broader market access.

• Successful commercial launch and initial market penetration of the MyoVista wavECG device in targeted healthcare settings, demonstrating early adoption and revenue generation.
• Formation of strategic partnerships or licensing agreements with larger medical device companies or healthcare providers to expand the reach and integration of MyoVista Insights.
• Publication of positive clinical study results demonstrating the superior diagnostic accuracy and clinical utility of HeartSciences' AI-ECG solutions compared to conventional methods.

What Are the Key Risks for HSCS?

Financial-distress signal — its Altman Z-Score of -27.61 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant financial losses and negative margins (Profit Margin: -97881.0%, Gross Margin: -1060.2%) indicate ongoing capital requirements and potential for dilutive financing.
• Small market capitalization ($7.32M) makes the company highly vulnerable to market fluctuations and investor sentiment, potentially impacting stock price volatility (Beta: 1.97).
• Difficulty in securing additional funding necessary for continued research and development, clinical trials, and scaling commercialization efforts in a capital-intensive industry.
• Intense competition from both established medical device companies and other emerging AI diagnostic firms, which could limit market share and pricing power.
• Challenges in obtaining and maintaining regulatory approvals for its AI-ECG devices and algorithms, which are critical for market entry and commercial success.

What Are the Growth Opportunities for HSCS?

• Expansion of AI-ECG Algorithm Adoption: The primary growth opportunity lies in the widespread adoption of HeartSciences' AI-ECG algorithms, particularly for detecting impaired cardiac relaxation. With the global market for cardiac diagnostics continuously expanding due to aging populations and rising cardiovascular disease prevalence, the demand for more precise and earlier detection methods is high. The MyoVista Insights cloud platform enables these algorithms to be integrated into various existing ECG hardware systems, potentially unlocking a vast market beyond the company's proprietary device. Successful clinical validation and regulatory approvals will be crucial for market penetration, with a timeline extending over the next 3-5 years as healthcare providers seek to leverage AI for improved diagnostic accuracy and efficiency.
• Commercialization and Market Penetration of MyoVista wavECG: The MyoVista wavECG device, a 12-lead resting ECG offering comprehensive cardiac function diagnostics, presents a significant commercialization opportunity. As a standalone device, it can directly compete with traditional ECG systems by offering superior diagnostic depth. The market for resting ECG devices is mature but ripe for innovation that provides enhanced clinical utility. Focusing on key markets with high cardiovascular disease burdens and strong healthcare infrastructure, HeartSciences can target hospitals, cardiology clinics, and primary care physicians. A successful go-to-market strategy, backed by clinical evidence and physician education, could drive substantial revenue growth over the medium term (2-4 years).
• Development of New AI-ECG Algorithms and Applications: Beyond its current algorithm for impaired cardiac relaxation, HeartSciences has the opportunity to develop and commercialize additional AI-ECG algorithms targeting other forms of cardiac dysfunction or specific cardiac conditions. The underlying MyoVista Insights platform is designed to host various algorithms, creating a scalable framework for future innovation. This could include algorithms for detecting early signs of heart failure, specific arrhythmias, or other structural heart diseases. Expanding the portfolio of AI-ECG applications would broaden the company's addressable market and strengthen its intellectual property, with new algorithm development and validation cycles typically spanning 2-5 years.
• Strategic Partnerships and Licensing Agreements: HeartSciences can accelerate its market penetration and technology adoption through strategic partnerships with larger medical device manufacturers or pharmaceutical companies. Licensing its AI-ECG algorithms to established players with extensive sales and distribution networks could provide a faster route to market and significant revenue streams without requiring massive internal scaling. Collaborations with pharmaceutical companies could also explore the use of AI-ECG in drug development and monitoring therapeutic efficacy for cardiovascular treatments. Such partnerships could materialize within the next 1-3 years, offering a capital-efficient growth pathway.
• Geographic Expansion into International Markets: While the initial focus may be on the US market, HeartSciences has a substantial opportunity for international expansion. Cardiovascular diseases are a global health challenge, and many developed and emerging markets are actively seeking advanced diagnostic solutions. Obtaining regulatory approvals in key international markets (e.g., Europe, Asia-Pacific) and establishing distribution channels would open up new revenue streams. Tailoring commercialization strategies to local healthcare systems and regulatory environments would be critical, with a long-term timeline (3-7 years) for significant international market penetration.

What Threats Does HSCS Face?

• Intense competition from established medical device manufacturers and emerging AI diagnostic companies.
• Stringent and evolving regulatory landscape for medical devices and AI-driven diagnostics.
• Challenges in securing adequate funding for continued R&D, clinical trials, and commercialization efforts.
• Rapid technological advancements by competitors could diminish the competitive advantage of current offerings.

What Are HSCS's Competitive Advantages?

• Proprietary AI Algorithms: Development of specialized AI algorithms for detecting specific cardiac dysfunctions like impaired cardiac relaxation, offering unique diagnostic capabilities.
• Integrated Device and Platform: The combination of the MyoVista wavECG device and the MyoVista Insights cloud platform provides a comprehensive, integrated solution for AI-ECG.
• Enhanced Clinical Utility: Ability to provide more comprehensive diagnostic information beyond conventional ECGs, potentially leading to earlier and more accurate diagnoses.
• Regulatory Hurdles: Successful navigation of regulatory approvals for novel AI-ECG devices and algorithms creates a barrier to entry for new competitors.

What Does HSCS Do?

HeartSciences Inc., established in 2007 and headquartered in Southlake, Texas, is a medical technology company dedicated to advancing cardiac diagnostics through the integration of artificial intelligence (AI) with electrocardiograms (ECGs). Originally known as Heart Test Laboratories, Inc., the company underwent a rebranding to HeartSciences Inc. in October 2024, signaling its sharpened focus on AI-driven solutions. The core mission of HeartSciences is to augment the clinical utility of traditional ECGs, transforming them into more comprehensive diagnostic tools for cardiac function. The company's primary offerings revolve around its AI-enhanced ECG (AI-ECG) solutions. A key product is the MyoVista wavECG device, a sophisticated 12-lead resting ECG system. Unlike conventional ECGs, the MyoVista wavECG provides extensive diagnostic information related to cardiac function, including the detection of impaired cardiac relaxation or other forms of cardiac dysfunction, whether stemming from heart disease or the natural aging process. This capability allows for a more in-depth assessment of a patient's cardiac health from a single, routine examination. Complementing its hardware, HeartSciences also offers MyoVista Insights, a cloud-based platform. This platform is designed to host the company's proprietary AI-ECG algorithms, enabling their deployment across various existing ECG hardware systems. This strategic approach allows for broader applicability and integration of HeartSciences' AI capabilities within the existing healthcare infrastructure, potentially expanding its market reach beyond its own MyoVista device. With a team of 15 employees, HeartSciences operates within the Medical Devices industry, positioning itself at the intersection of cardiology and artificial intelligence to address the growing demand for advanced, non-invasive cardiac diagnostic tools. The company's focus on early detection and comprehensive cardiac assessment positions it as an innovator in the evolving landscape of cardiovascular care.

What Products and Services Does HSCS Offer?

• Develops AI-enhanced electrocardiogram (AI-ECG) solutions for cardiac diagnostics.
• Offers the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive cardiac function data.
• Integrates artificial intelligence to detect impaired cardiac relaxation and other cardiac dysfunctions.
• Provides MyoVista Insights, a cloud-based platform for hosting AI-ECG algorithms across various ECG hardware systems.
• Aims to augment the clinical utility of conventional ECGs with advanced diagnostic information.
• Focuses on early detection of heart disease and cardiac dysfunction, whether age-related or disease-induced.
• Operates in the medical technology sector, specifically within the medical devices industry.

How Does HSCS Make Money?

• Device Sales: Generates revenue from the direct sale of its MyoVista wavECG devices to healthcare providers, hospitals, and clinics.
• Software/Platform Subscriptions: Earns recurring revenue through subscriptions or licensing fees for its MyoVista Insights cloud platform and access to its AI-ECG algorithms.
• Algorithm Licensing: Potentially licenses its proprietary AI-ECG algorithms to other medical device manufacturers for integration into their existing or future ECG systems.
• Service & Support: May offer maintenance, support, and training services for its devices and software, contributing to ongoing revenue streams.

What Industry Does HSCS Operate In?

HeartSciences Inc. operates within the dynamic Medical Devices industry, specifically targeting the cardiovascular diagnostics segment with its AI-enhanced ECG (AI-ECG) solutions. This sector is experiencing significant transformation, driven by advancements in artificial intelligence, increasing prevalence of cardiovascular diseases, and a growing demand for non-invasive, early detection tools. The global market for ECG devices is substantial, with AI integration poised to unlock new diagnostic capabilities and improve clinical workflows. HeartSciences positions itself as an innovator by directly addressing the limitations of conventional ECGs, which often provide basic electrical activity data but lack comprehensive functional insights. Its MyoVista wavECG device and MyoVista Insights platform aim to provide more detailed information on cardiac dysfunction, whether age-related or disease-induced. The competitive landscape includes established medical device manufacturers with traditional ECG offerings, as well as emerging AI-focused diagnostic companies. HeartSciences seeks to differentiate itself through its proprietary algorithms designed for specific cardiac relaxation impairments, aiming to carve out a niche in advanced, AI-driven cardiac assessment.

Who Are HSCS's Key Customers?

• Hospitals and healthcare systems seeking advanced cardiac diagnostic tools.
• Cardiology clinics and specialists requiring more comprehensive ECG data for patient assessment.
• Primary care physicians looking for improved early detection capabilities for cardiac dysfunction.
• Potentially, research institutions and pharmaceutical companies for clinical trials and drug development.

Over the past six months, HeartSciences Inc. insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 450K shares acquired (about $0) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: HeartSciences Inc.

Revenue for HeartSciences Inc. came in at $0 during Q3 FY2026. The company recorded a net loss of $2.0M, with diluted EPS of $-0.63. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, HSCS averaged $-1.02 in diluted EPS.

HSCS Valuation & Market Position

With a $7.32M market cap, HeartSciences Inc. sits in the micro-cap segment of the market. Relative to its peer group, HSCS's quantitative score of 16/100 is below the peer average of 49/100.

Key Financial Metrics

A current ratio of 1.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -159.7%, the inverse of the P/E and a quick read on earnings relative to price.

HeartSciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.61 places it in the distress zone, a signal of elevated financial risk.

HeartSciences Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.1% above estimates on average.

Company Profile

HeartSciences Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Southlake, US. The company is led by CEO Andrew Simpson. HSCS has traded publicly since 2022.

HSCS Financials

HSCS Latest News

HSCS Analyst Consensus

HSCS MoonshotScore

HeartSciences Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources